A discussion on the FDA approved treatment option, capmatinib, and FDA breakthrough therapy designation, tepotinib, for treatment of mNSCLC with MET exon 14 mutations.
Data from the following clinical trials are discussed:
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small cell lung cancer: results from cohort 6 of the phase 2 GEOMETRY mono-1 study. (Groen HJM et al. 2020 ASCO annual meeting. Abstract 9520.)
Tepotinib in non–small cell lung cancer with MET exon 14 skipping mutations. (Paik PK et al. N Engl J Med. 2020;383:931-943.)